Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Holding(s) in Company

17 Jan 2017 14:46

RNS Number : 3878U
Synairgen plc
17 January 2017
Β 

Β 

Β 

Β 

Β 

Β 

Β 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

Β 

Β 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Synairgen plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

Β 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify):

Β 

Β 

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)Β (if different from 3.):iv

Β 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

16 January 2017

6. Date on which issuer notified:

17 January 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Β > 11%

Β Β Β Β Β Β 
Β 

Β 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1p

9,450,512

9,450,512

10,136,512

10,136,512

Β 

11.09%

Β 

GB00B0381Z20

Β 

Β 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

Β 

Β 

Β 

Β 

Β 

Β 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

Β 

% of voting rights xix, xx

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Nominal

Delta

Β 

Β 

Β 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,136,512

11.09%

Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β 
Β 

Β 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Β 

Blake Holdings Limited

4,146,512

Seren Investment Management Limited

5,345,000

Richard Griffiths direct holdings

645,000

Β 

Β 

Total

10,136,512

Β 

Β 

The above undertakings are all controlled by Richard Griffiths

Β 

Β 

Proxy Voting:

10. Name of the proxy holder:

Β 

11. Number of voting rights proxy holder will ceaseto hold:

Β 

12. Date on which proxy holder will cease to holdvoting rights:

Β 

Β 

13. Additional information:

Β 

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+44 1534 719761

Β Β Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLLLFSSLEIDLID
Date   Source Headline
9th Apr 20257:00 amRNSCancellation - Synairgen plc
3rd Apr 20257:00 amRNSUpdate on trading post cancellation
28th Mar 20252:21 pmRNSResult of General Meeting
11th Mar 20257:00 amRNSProposed cancellation of trading on AIM
17th Jan 202512:55 pmRNSHolding(s) in Company
16th Jan 20253:42 pmRNSMartin Murphy appointed as Non-Executive Director
16th Jan 20253:42 pmRNSResult of General Meeting and Total Voting Rights
15th Jan 20255:37 pmRNS£18m raised to fund Phase 2 INVENT clinical trial
20th Dec 20247:00 amRNSProposed Fundraising
30th Oct 20246:09 pmRNSExercise of Share Options and Total Voting Rights
10th Oct 20245:05 pmRNSResults of AGM and Appointment of New Chairman
26th Sep 20247:00 amRNSInterim Results
18th Sep 20247:00 amRNSAppointment of New Chairman and Notice of AGM
5th Sep 20247:00 amRNSBoard Change
27th Jun 20247:00 amRNS2023 Full Year Results
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.